ENDRA Life Sciences Commences Staking of HYPE Digital Asset Holdings, Reinforcing Long-Term Strategy with Anchorage Digital and ARCA

ENDRA is converting static treasury assets into a dynamic rewards engine to support medical innovation

ANN ARBOR, Mich.--(BUSINESS WIRE)-- ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer in imaging technologies for the early detection and monitoring of metabolic dysfunction associated liver disease (“MASLD”) and metabolic dysfunction associated steatohepatitis (“MASH”), today announced a significant step in its digital asset strategy with the commencement of staking its holdings of HYPE, the native token of the Hyperliquid ecosystem.

This strategic move, guided by ARCA Investment Management, LLC, and secured by Anchorage Digital, is designed to maximize the utility and return of the Company's HYPE treasury while actively contributing to the security and decentralization of the underlying blockchain network. Following the initial investment announced on October 23, 2025, ENDRA has successfully deployed its HYPE position into a secure, institutional-grade staking solution.

“Commencing our HYPE staking program is an essential evolution of our digital asset strategy,” said Alexander Tokman, Chief Executive Officer of ENDRA. “By partnering with industry leaders ARCA and Anchorage Digital, we are not just purchasing digital assets – we are putting capital to work in a productive, reward generating way, all within a robust and compliant institutional framework.”

Key benefits of the staking initiative include the following:

• Reward Generation: Staking its HYPE assets enables ENDRA to generate consistent network incentives, which is expected to enhance shareholder value over the long term. This provides measurable asset compensation.
• Network Security & Support: By participating in the staking mechanism, ENDRA is actively securing the Hyperliquid network, aligning its corporate interests with the health and stability of the digital asset ecosystem.
• Strategic Participation: Staking provides ENDRA with enhanced access and optionality within the broader Hyperliquid ecosystem, including potential future governance rights and participation in decentralized finance (“DeFi”) opportunities.

This fundamental, bottoms-up approach to selecting assets like HYPE offers ENDRA the ability to earn compensation while diversifying its balance sheet assets. ARCA Investment Management’s role is to combine crypto-native expertise with traditional risk management to deliver disciplined, transparent solutions across market cycles. This staking initiative is an example of strategic success in the DeFi space.

Institutional participation in digital asset incentive opportunities requires the highest standards of security and regulatory compliance. Anchorage Digital Bank, the only federally chartered and regulated digital asset provider, delivers institutional‑grade custody and integrated staking services that enable ENDRA to engage prudently with this asset class.

ENDRA will continue to monitor the digital asset landscape for opportunities that align with its disciplined, growth-focused treasury management strategy.

About ENDRA Life Sciences Inc.

ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (“TAEUS^®”), a ground-breaking technology being developed to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS^® is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. ENDRA also has launched a digital asset treasury strategy directed at the highest conviction holdings of Arca Investment Management, LLC in the DeFi sector, beginning with the cryptocurrencies of the pioneering decentralized exchanges and protocols, with a focus on perpetual futures such as HYPE. For more information, please visit www.endrainc.com.

Forward-Looking Statements

All statements in this press release that are not based on historical fact are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of terms such as “approximate,” “anticipate,” “attempt,” “believe,” “could,” “estimate,” “expect,” “forecast,” “future,” “goal,” “hope,” “intend,” “may,” “plan,” “possible,” “potential,” “project,” “seek,” “should,” “will,” “would,” or other comparable terms (including the negative of any of the foregoing), although some forward-looking statements are expressed differently. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others: the results of the proposed offering; expectations regarding our DAT strategy and ability to execute such strategy successfully; our limited commercial and DAT experience, limited cash and history of losses; our ability to obtain adequate financing to fund our business operations or DAT strategy in the future; risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; regulatory developments related to crypto assets and crypto asset markets; a determination that we are an investment company under the Investment Company Act of 1940; any changes in the accounting treatment of cryptocurrency holdings; the risk that the price of the Company's common stock may be highly correlated to the price of the digital assets that it holds; our ability to achieve profitability; delays and changes in regulatory requirements, policy and guidelines, including laws and accounting rules applicable to digital assets and potential delays in submitting required regulatory applications or other submissions with respect to U.S. Food and Drug Administration (“FDA”) or other regulatory agency approval; our ability to obtain and maintain required CE mark certifications and secure required FDA and other governmental approvals for our Thermo-Acoustic Enhanced Ultrasound (“TAEUS”) applications; our ability to develop any commercially feasible applications based on our TAEUS technology; market acceptance of our technology; the effect of macroeconomic conditions on our business; results of our human studies, which may be negative or inconclusive; our ability to find and maintain development partners; our reliance on third parties, collaborations, strategic alliances and licensing arrangements to complete our TAEUS business strategy; the amount and nature of competition in the healthcare industry; our ability to protect our intellectual property; potential changes in the healthcare industry or third-party reimbursement practices; our ability to comply with regulation by various federal, state, local and foreign governmental agencies and to maintain necessary regulatory clearances or approvals; our ability to regain compliance with Nasdaq listing standards; our dependence on our senior management team; and the other risks and uncertainties described in the Risk Factors and Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of the Company’s most recent Annual Report on Form 10-K and in subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission and the Risk Factors sections of the preliminary prospectus describing the terms of the proposed offering filed with the SEC. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release speak only as of the date of issuance, and ENDRA assumes no obligation to update any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251113934707/en/

Company Contact:

Investor Relations

investors@endrainc.com

www.endrainc.com

Investor Relations Contact:

Yvonne Briggs

Alliance Advisors IR

(310) 691-7100

ybriggs@allianceadvisors.com

Source: ENDRA Life Sciences Inc.